Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees

被引：0

作者：

Babs E Verstrepen ^{[1
]}

André Boonstra ^{[2
]}

Gerrit Koopman ^{[1
]}

机构：

[1] Department of Virology,Biomedical Primate Research Centre,2280GH Rijswijk,The Netherlands

[2] Department of Gastroenterology and Hepatology,Erasmus University Medical Center Rotterdam,3015 CE Rotterdam,The Netherlands

来源：

World Journal of Hepatology | 2015年 / 01期

关键词：

Hepatitis C virus; Vaccines; Chimpanzees; Review; Prophylactic; Antibodies; T-cells;

D O I：

暂无

中图分类号：

R512.63 [];

学科分类号：

100401 ;

摘要：

Hepatitis C virus(HCV) infection is characterized by a high propensity for development of life-long viral persistence. An estimated 170 million people suffer from chronic hepatitis caused by HCV. Currently,there is no approved prophylactic HCV vaccine available.With the near disappearance of the most relevant animal model for HCV,the chimpanzee,we review the progression that has been made regarding prophylactic vaccine development against HCV. We describe the results of the individual vaccine evaluation experiments in chimpanzees,in relation to what has been observed in humans. The results of the different studies indicate that partial protection against infection can be achieved,but a clear correlate of protection has thus far not yet been defined.

引用

页码：53 / 69

页数：17

共 50 条

[31] The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide [J].

Perz, Joseph F. ;

Armstrong, Gregory L. ;

Farrington, Leigh A. ;

Hutin, Yvan J. F. ;

Bell, Beth P. .

JOURNAL OF HEPATOLOGY, 2006, 45 (04) :529-538

[32] Duplication and divergence in humans and chimpanzees [J].

Wooding, S ;

Jorde, LB .

BIOESSAYS, 2006, 28 (04) :335-338

[33]

Michela Brazzoli,Ari Helenius,Steven K.H. Foung,Michael Houghton,Sergio Abrignani,Marcello Merola.Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells[J].Virology,2004(1)

[34]

Geert Leroux-Roels,Erik Depla,Frank Hulstaert,Leen Tobback,Stéphanie Dincq,Jaques Desmet,Isabelle Desombere,Geert Maertens.A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers[J].Vaccine,2004(23)

[35]

J.Tilman Gerlach,Helmut M Diepolder,Reinhart Zachoval,Norbert H Gruener,Maria-Christina Jung,Axel Ulsenheimer,Winfried W Schraut,C.albrecht Schirren,M Waechtler,M Backmund,Gerd R Pape.Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance 1 1 The Bundesministerium für Bildung und Forschung and the European Union, as sponsors of the study, had no role in study design, data collection, analysis, or interpretation or in the writing and the decision to submit the repo

[36]

Montserrat Puig,Marian E Major,Kathleen Mihalik,Stephen M Feinstone.Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection[J].Vaccine,2003(8)

[37] Protection against persistence of hepatitis C [J].

Mehta, SH ;

Cox, A ;

Hoover, DR ;

Wang, XH ;

Mao, Q ;

Ray, S ;

Strathdee, SA ;

Vlahov, D ;

Thomas, DL .

LANCET, 2002, 359 (9316) :1478-1483

[38]

Patrizia Farci.Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome[Science 1989;244:359–362][J].Journal of Hepatology,2002(5)

[39] Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency [J].

Razvi, S ;

Schneider, L ;

Jonas, MM ;

Cunningham-Rundles, C .

CLINICAL IMMUNOLOGY, 2001, 101 (03) :284-288

[40] Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV [J].

Forns, X ;

Payette, PJ ;

Ma, XY ;

Satterfield, W ;

Eder, G ;

Mushahwar, IK ;

Govindarajan, S ;

Davis, HL ;

Emerson, SU ;

Purcell, RH ;

Bukh, J .

HEPATOLOGY, 2000, 32 (03) :618-625

← 1 2 3 4 5 →